Open Source Securities atribui à 诺诚健华 uma classificação de "Compra": a empresa inverterá prejuízos até 2025, com a aceleração da expansão global de múltiplos produtos

每经AI快讯，开源证券3月29日发布研报称，给予诺诚健华（688428.SH，最新价：25.3元）"买入"评级。
A Every Daily AI news, a Open Source Securities released a report on March 29, giving Nuo Cheng Jian Hua (688428.SH, latest price: 25.3 yuan) a “buy” rating.
评级理由主要包括：1）2025年奥布替尼快速放量，公司营收强劲增长，超前实现扭亏为盈；
The reasons for the rating mainly include: 1) Rapid release of Obinutuzumab in 2025, strong growth in company revenue, and early realization of profitability;
2）血液瘤领域产品矩阵逐步丰盈，首个实体瘤产品获批上市；
2) The product matrix in the field of hematological tumors is gradually enriching, and the first solid tumor product has been approved for上市;
3）深耕自免蓝海市场，2026年多管线迎来关键节点。
3) Deeply cultivating the self-immune blue ocean market, and multiple pipelines will迎来关键节点 in 2026.
风险提示：医药监管政策变动、汇率波动、公司核心成员流失等。
Risk reminder: Changes in pharmaceutical regulatory policies, exchange rate fluctuations, loss of key company members, etc.

每经头条（nbdtoutiao）——美伊战争，“石油美元黄昏”！
A Every Daily headline (nbdtoutiao) - The US-Iran war, “The Twilight of Petrodollar”!
美国无力保护海湾国家，石油贸易加速去美元，英国财政部前大臣：投靠美国再也无法换取安全保障！
The United States is unable to protect Gulf countries, oil trade is accelerating the move away from the dollar, and the former UK Treasury Secretary: relying on the US can no longer guarantee security!

（记者 张喜威）
(Reporter Zhang Xiwei)

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use.
据此操作，风险自担。
Operate accordingly, risk is self-borne.

每日经济新闻
Every Daily Economic News